Zealand Pharma Shares Plunge on High Dropout Rates in Survodutide Data
businessstockssciencepharma 1 posts · 1 accounts
Shares of Danish biotech Zealand Pharma fell after detailed data on its weight-loss drug survodutide showed patient dropout rates far above those of leading treatments. The results led analysts to slash peak sales forecasts and rethink the company’s obesity strategy.
With enthusiasm for survodutide cooling, investors are shifting attention to petrelintide, Zealand’s amylin-based medicine, as the next potential driver of the stock.
From the sources (1 posts)
@cnbcShares of Danish biotech Zealand Pharma recently plunged after detailed data on its weight loss drug survodutide showed far higher patient dropout rates than leading treatments, prompting analysts to slash peak sales forecasts and rethink t